Online inquiry

IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11394MR)

This product GTTS-WQ11394MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDGFRA gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001347829.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5156
UniProt ID P16234
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11394MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8697MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ13237MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ538MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ12239MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ4818MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ15624MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ1768MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ2115MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW